LOX and Alzheimer disease: Overall, new triazole–coumarin conjugates (8l and 8n) were presented in this study, having acceptable LOX inhibition activity, good anti-BuChE potency, valuable neuroprotection, remarkable anti-Aβ aggregation, and significant antioxidant activity as potential MTDLs against AD.